poisar

Stocks · News reference

TG Therapeutics Raises FY2026 Sales Guidance from $950.000M to $1.000B vs $960.306M Est

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    TG Therapeutics Q3 2026 Earnings Call Transcript

    TG Therapeutics (NASDAQ:TGTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.